VVector Bio

Publications

Home
/
Publications

Publications

The founders and directors of VVector Bio have been associated with McGill University contributing to several publications in the field where some are listed below:

Fulber JPC, Farnós O, Kiesslich S, Yang Z, Dash S, Susta L, Wootton SK, Kamen AA. Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures. Vaccines (Basel). 2021 Nov 16;9(11):1335. doi: 10.3390/vaccines9111335. PMID: 34835266; PMCID: PMC8623276.

Joshi PRH, Venereo-Sanchez A, Chahal PS, Kamen AA. Advancements in molecular design and bioprocessing of recombinant adeno-associated virus gene delivery vectors using the insect-cell baculovirus expression platform. Biotechnol J. 2021 Apr;16(4):e2000021. doi: 10.1002/biot.202000021. Epub 2021 Jan 25. PMID: 33277815.

Farnós O, Venereo-Sánchez A, Xu X, Chan C, Dash S, Chaabane H, Sauvageau J, Brahimi F, Saragovi U, Leclerc D, Kamen AA. Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation. Vaccines (Basel). 2020 Nov 4;8(4):654. doi: 10.3390/vaccines8040654. PMID: 33158147; PMCID: PMC7712309.

Farnós O, Gelaye E, Trabelsi K, Bernier A, Subramani K, Kallel H, Yami M, Kamen AA. Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa. Vaccines (Basel). 2020 Jun 26;8(2):338. doi: 10.3390/vaccines8020338. PMID: 32604755; PMCID: PMC7350225.

Venereo-Sánchez A, Fulton K, Koczka K, Twine S, Chahal P, Ansorge S, Gilbert R, Henry O, Kamen A. Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF. 2019 Nov 8;37(47):7100-7107. doi: 10.1016/j.vaccine.2019.07.057. Epub 2019 Jul 26. PMID: 31358407.

Milián E, Julien T, Biaggio R, Venereo-Sanchez A, Montes J, Manceur AP, Ansorge S, Petiot E, Rosa-Calatrava M, Kamen AA. Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics. Vaccine. 2017 Jun 8;35(26):3423-3430. doi: 10.1016/j.vaccine.2017.04.065. Epub 2017 May 8. PMID: 28495315.

Venereo-Sanchez A, Simoneau M, Lanthier S, Chahal P, Bourget L, Ansorge S, Gilbert R, Henry O, Kamen A. Process intensification for high yield production of influenza H1N1 Gag virus-like particles using an inducible HEK-293 stable cell line. 2017 Jul 24;35(33):4220-4228. doi: 10.1016/j.vaccine.2017.06.024. Epub 2017 Jun 22. PMID: 28648546.

Venereo-Sanchez A, Gilbert R, Simoneau M, Caron A, Chahal P, Chen W, Ansorge S, Li X, Henry O, Kamen A. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate. 2016 Jun 17;34(29):3371-80. doi: 10.1016/j.vaccine.2016.04.089. Epub 2016 May 5. PMID: 27155499.

Emmerling VV, Pegel A, Milian EG, Venereo-Sanchez A, Kunz M, Wegele J, Kamen AA, Kochanek S, Hoerer M. Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells. Biotechnol J. 2016 Feb;11(2):290-7. doi: 10.1002/biot.201500176. Epub 2015 Sep 24. PMID: 26284700.

Toussaint C, Henry O, Durocher Y. Metabolic engineering of CHO cells to alter lactate metabolism during fed-batch cultures. J Biotechnol. 2016 Jan 10;217:122-31. doi: 10.1016/j.jbiotec.2015.11.010. Epub 2015 Nov 18. PMID: 26603123.

Biaggio RT, Abreu-Neto MS, Covas DT, Swiech K. Serum-free suspension culturing of human cells: adaptation, growth, and cryopreservation. Bioprocess Biosyst Eng. 2015 Aug;38(8):1495-507. doi: 10.1007/s00449-015-1392-9. Epub 2015 Mar 31. PMID: 25822314.

Sánchez O, Barrera M, Farnós O, Parra NC, Salgado ER, Saavedra PA, Meza CD, Rivas CI, Cortez-San Martín M, Toledo JR. Effectiveness of the E2-classical swine fever virus recombinant vaccine produced and formulated within whey from genetically transformed goats. Clin Vaccine Immunol. 2014 Dec;21(12):1628-34. doi: 10.1128/CVI.00416-14. Epub 2014 Oct 1. PMID: 25274802; PMCID: PMC4248785.

Picanco-Castro V, Biaggio RT, Cova DT, Swiech K. Production of recombinant therapeutic proteins in human cells: current achievements and future perspectives. Protein Pept Lett. 2013 Dec;20(12):1373-81. doi: 10.2174/092986652012131112130322. PMID: 24261981.

Fernández E, Toledo JR, Chiong M, Parra F, Rodríguez E, Montero C, Méndez L, Capucci L, Farnós O. Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration. Vet Immunol Immunopathol. 2011 Aug 15;142(3-4):179-88. doi: 10.1016/j.vetimm.2011.05.007. Epub 2011 May 7. PMID: 21621855.

Pose AG, Gómez JN, Sánchez AV, Redondo AV, Rodríguez ER, Seguí RM, Ramos EM, Moltó MP, Rodríguez ES, Cordero LR, Mallón AR, Nordelo CB. Subunit influenza vaccine candidate based on CD154 fused to HAH5 increases the antibody titers and cellular immune response in chickens. Vet Microbiol. 2011 Sep 28;152(3-4):328-37. doi: 10.1016/j.vetmic.2011.05.033. Epub 2011 May 25. PMID: 21680114.

Sánchez O, Barrera M, Rodríguez MP, Frías MT, Figueroa NE, Naranjo P, Montesino R, Farnos O, Castell S, Venereo A, Ganges L, Borroto C, Toledo JR. Classical swine fever virus E2 glycoprotein antigen produced in adenovirally transduced PK-15 cells confers complete protection in pigs upon viral challenge. 2008 Feb 13;26(7):988-97. doi: 10.1016/j.vaccine.2007.11.014. Epub 2007 Nov 26. PMID: 18192093.

Process
Development

Cell Line Development

Pre-clinical manufacturing

Analytical Development

VVECTOR BIO, Bridging Research and Clinic

2020 VVECTOR BIO. All Rights Reserved